Clinical Review: Update on Treatment of Inflammatory Macular Edema

REFERENCES

• van Kooij B, Probst K, Fijnheer R, et al. Risk factors for cystoid macular oedema in patients with uveitis. Eye. 2008;22(2):256–260.
   PubMed Web of Science ®Google Scholar
• Thorne JE, Daniel E, Jabs DA, et al. Smoking as a risk factor for cystoid macular edema complicating intermediate uveitis. Am J Ophthalmol. 2008;145(5):841–846.
   PubMed Web of Science ®Google Scholar
• Markomichelakis NN, Halkiadakis I, Pantelia E, et al. Course of macular edema in uveitis under medical treatment. Ocul Immunol Inflamm. 2007;15(2):71–79.
   PubMed Web of Science ®Google Scholar
• Lardenoye CW, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006; 113:1446–1449.
   PubMed Web of Science ®Google Scholar
• Venkatesh P, Abhas Z, Garg S, et al. Prospective optical coherence tomographic evaluation of the efficacy of oral and posterior subtenon corticosteroids in patients with intermediate uveitis. Graefes Arch Clin Exp Ophthalmol. 2007; 245:59–67.
   PubMed Web of Science ®Google Scholar
• Rothova A. Inflammatory cystoid macular edema. Curr Opin Ophthalmol. 2007;18(6):487–492.
   PubMed Web of Science ®Google Scholar
• Tranos PG, Wickremasinghe SS, Stangos NT, et al. Macular edema. Surv Ophthalmol. 2004;49:470–490.
   PubMed Web of Science ®Google Scholar
• Yannuzzi LA. A perspective on the treatment of aphakic cystoid macular edema. Surv Ophthalmol. 1984;28 (Suppl):540–553.
   Google Scholar
• Miyake K. Prevention of cystoid macular edema after lens extractrion by topical indomethacin (I). A preliminary report. Albr v Graefes Arch Klin Exp Ophthal. 1977; 203: 81–88.
   PubMedGoogle Scholar
• Lardenoye CW, van Schooneveld MJ, Treffers WF, et al. Grid laser photocoagulation for macular edema in uveitis or the Irvine-Gass syndrome. Br J Ophthalmol. 1998;82:1013–1016.
   PubMedGoogle Scholar
• Tugal-Tutkun I, Herbort CA, Khairallah M; The Angiography Scoring for Uveitis Working Group (ASUWOG). Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol. 2008 Sep 16. [Epub ahead of print]
   Google Scholar
• Watanabe A, Arimoto S, Nishi O. Correlation between metamorphopsia and epiretinal membrane optical coherence tomography findings. Ophthalmology. 2009;116:1788–1793.
   Google Scholar
• Hsu J. Drug delivery methods for posterior segment disease. Curr Opin Ophthalmol. 2007;18:235–239.
   PubMed Web of Science ®Google Scholar
• Van Kooij B, De Boer J, Ten Dam N, et al. The effect of non-steroidal anti-inflammatory drugs on inflammatory cystoid macular edema. Am J Ophthalmol. 2005; 140(3):563–564.
   Google Scholar
• Soheilian M, Karimi S, Ramezani A, et al. Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina. 2010; 30(3):509–515.
   Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513.
   PubMed Web of Science ®Google Scholar
• Tamesis RR, Rodriguez A, Christen WG, et al. Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. Ophthalmology. 1996;103:768–775.
   PubMed Web of Science ®Google Scholar
• Venkatesh P, Kumar CS, Abbas Z, et al. Comparison of the efficacy and safety of different methods of posterior subtenon injection. Ocul Immunol Inflamm. 2008;16:217–223.
   PubMed Web of Science ®Google Scholar
• Byun YS, Park YH. Complications and safety profile of posterior subtenon injection of triamcinolone acetonide. J Ocul Pharmacol Ther. 2009;25:159–162.
   PubMed Web of Science ®Google Scholar
• Cunningham MA, Edelman JL, Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol. 2008;53:139–149.
   PubMed Web of Science ®Google Scholar
• Roth DB, Verma V, Realini T, et al. Long-term incidence and timing of intraocular hypertension after intravitreale triamcinolone acetonide injection. Ophthalmology. 2009;116:455–460.
   Google Scholar
• Jonas JB, Schlichtenbrede F. Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases. Eye. 2008;22:869–873.
   PubMed Web of Science ®Google Scholar
• Galor A, Margolis R, Brasil OM, et al. Adverse events after intravitreal triamcinolone in patients with and without uveitis. Ophthalmology. 2007;114:1912–1918.
   PubMed Web of Science ®Google Scholar
• Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol. 2003;121:667–673.
   PubMed Web of Science ®Google Scholar
• Hirano Y, Ito T, Nozaki M, et al. Intraocular pressure elevation following triamcinolone acetonide administration as related to administration routes. Jpn J Ophthalmol. 2009;53:519–522.
   PubMed Web of Science ®Google Scholar
• Breusegem C, Vandewalle E, Van Calster J, et al. Predictive value of a topical dexamethasone provocative test before intravitreal triamcinolone acetonide injection. Invest Ophthalmol Vis Sci. 2009;50:573–576.
   PubMed Web of Science ®Google Scholar
• Lin JM, Tsai YY, Chiu YT, et al. Paracentesis before or after intravitreal injection of triamcinolone acetonide and its necessity? Am J Ophthalmol. 2005;140:695–702.
   Google Scholar
• Bhavsar AR, Ip MS, Glassman AR; DRCRnet and the SCORE Study Groups. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCR net and SCORE clinical trials. Am J Ophthalmol. 2007;144:454–456.
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kreissig I, Spandau UH, et al. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol. 2006;141:579–580.
   PubMed Web of Science ®Google Scholar
• Taban M, Singh RP, Chung JY, et al. Sterile endophthalmitis after intravitreal triamcinolone: a possible association with uveitis. Am J Ophthalmol. 2007;144:50–54.
   PubMed Web of Science ®Google Scholar
• Das-Bhaumik RG, Jones NP. Low-dose intraocular triamcinolone injection for intractable macular oedema and inflammation in patients with uveitis. Eye. 2006;20:934–937.
   PubMedGoogle Scholar
• Jonas JB, Schlichtenbrede F. Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases. Eye. 2008;22:869–873.
   PubMed Web of Science ®Google Scholar
• Pavesio C, Zierhut M, Bairi K, et al. Fluocinolone Acetonide Study Group evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology. 2010 Jan 14. [Epub ahead of print]
   Google Scholar
• Callanan DG, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol. 2008:126(9):1191–1201.
   PubMed Web of Science ®Google Scholar
• Mohammad DA, Sweet BV, Elner SG. Retisert: is the new advance in treatment of uveitis a good one? Ann Pharmacother. 2007;41:449–454.
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonideimplants. Arch Ophthalmol. 2007;125(11):1478–1485.
   PubMedGoogle Scholar
• Bollinger KE, Smith SD. Prevalence and management of elevated intraocular pressure after placement of an intravitreal sustained-release steroid implant. Curr Opin Ophthalmol. 2009; 20(2):99–103.
   Google Scholar
• Jaffe GJ. Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis. Am J Ophthalmol. 2008;145:667–675.
   PubMed Web of Science ®Google Scholar
• Yeh S, Cebulla CM, Witherspoon SR, et al. Management of fluocinolone implant dissociation during implant exchange. Arch Ophthalmol. 2009;127:1218–1221.
   PubMed Web of Science ®Google Scholar
• Silva-Cunha A, Fialho SL, Naud MC, et al. Poly-epsilon-caprolactone intravitreous devices: an in vivo study. Invest Ophthalmol Vis Sci. 2009;50:2312–1218.
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Blumenkranz MS, Haller JA, et al. Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125:309–317.
   PubMed Web of Science ®Google Scholar
• Williams GA, Haller JA, Kuppermann BD, et al. Dexamethasone DDS Phase II Study Group. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol. 2009;147:1048–1054.
   PubMed Web of Science ®Google Scholar
• Shin JP, Park YC, Oh JH, et al. Biodegradable intrascleral implant of triamcinolone acetonide in experimental uveitis. J Ocul Pharmacol Ther. 2009;25:201–208.
   PubMed Web of Science ®Google Scholar
• Kuno N, Fujii S. Biodegradable intraocular therapies for retinal disorders: progress to date. Drugs Aging. 2010;27:117–134.
   PubMed Web of Science ®Google Scholar
• Ufret-Vincenty RL, Singh RP, Lowder CY, et al. Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant. Am J Ophthalmol. 2007;143:334–335.
   PubMed Web of Science ®Google Scholar
• Lane L, Tamesis R, Rodriguez A, et al. Systemic immunosuppressive therapy and the occurrence of malignancy in patients with ocular inflammatory disease. Ophthalmology. 1995;102:1530–1535.
   PubMed Web of Science ®Google Scholar
• Cox SN, Hay E, Bird AC.Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol. 1988;106:1190–1195.
   PubMed Web of Science ®Google Scholar
• Fishman GA, Apushkin MA. Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa. Br J Ophthalmol. 2007;91:743–745.
   PubMed Web of Science ®Google Scholar
• Misotten T, Van Laar JAM, Van der Loos Tl, et al. Octreotide long-acting repeatable for the treatment of chronic macular edema in uveitis. Am J Ophthalmol. 2007;144:838–843.
   Google Scholar
• Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med. 1990;172:1535–1545.
   PubMed Web of Science ®Google Scholar
• Hattori K, Dias S, Heissig B, et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med. 2001;193:1005–1014.
   PubMed Web of Science ®Google Scholar
• Reinders ME, Sho M, Izawa A, et al. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest. 2003;112:1655–1665.
   PubMed Web of Science ®Google Scholar
• Vinores SA, Chan CC, Vinores MA, et al. Increased vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGFbeta) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization. J Neuroimmunol. 1998;89(1–2):43–50.
   Google Scholar
• Weiss K, Steinbrugger I, Weger M, et al. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye. 2009;23:1812–1818.
   PubMed Web of Science ®Google Scholar
• Fine HF, Baffi J, Reed GF, et al. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol. 2001;132(5):794–796.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Savant V, Scott RA, et al. Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders. Invest Ophthalmol Vis Sci. 2007;48(5):2203–2207.
   Google Scholar
• Cervantes-Castañeda RA, Giuliari GP, Gallagher MJ, et al. Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up. Eur J Ophthalmol. 2009;19(4):622–629.
   PubMed Web of Science ®Google Scholar
• Mackensen F, Heinz C, Becker MD, et al. Intravitreal bevacizumab (Avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina. 2008;28(1):41–45.
   PubMed Web of Science ®Google Scholar
• Cordero Coma M, Sobrin L, Onal S, et al. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology. 2007;114(8):1574–1579. e1. Epub 2007 Mar 23.
   PubMed Web of Science ®Google Scholar
• Lott MN, Schiffman JC, Davis JL. Bevacizumab in inflammatory eye disease. Am J Ophthalmol. 2009;148(5):711–717. e2. Epub 2009 Aug 5.
   Google Scholar
• Mirshahi A, Djalilian A, Chams H, et al. Intravitreal bevacizumab (Avastin) for the treatment of cystoid macular edema in behçet disease. Ocul Immunol Inflamm. 2009;17:59–64.
   PubMed Web of Science ®Google Scholar
• Acharya NR, Hong KC, Lee SM. Ranibizumab for Refractory Uveitis-related Macular Edema. Am J Ophthalmol. 2009;148(2):303–309. e2. Epub 2009 May 9.
   Google Scholar
• Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina. 2008;28:1395–1399.
   PubMed Web of Science ®Google Scholar
• Ueta T, Yanagi Y, Tamaki Y, et al. Cerebrovascular accidents in ranibizumab. Ophthalmology. 2009;116(2):362.
   Google Scholar
• Moorthy S, Cheung N. Cerebrovascular accidents and ranibizumab. Ophthalmology. 2009;116(9):1834–1835.
   Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–1444.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431.
   PubMed Web of Science ®Google Scholar
• Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90(11):1344–1349. Epub 2006 Jul 19.
   PubMedGoogle Scholar
• Ladas ID, Karagiannis DA, Rouvas AA, et al. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina. 2009;29:313–318.
   PubMed Web of Science ®Google Scholar
• Okada AA, Keino H, Watanabe T, et al. Recurrence of acute anterior inflammation after intravitreal injection of bevacizumab in uveitis. Jpn J Ophthalmol. 2009;53(2):182–184. Epub 2009 Mar 31.
   Google Scholar
• Neri P, Mariotti C, Cimino L, et al. Long-term control of cystoid macular oedema in noninfectious uveitis with mycophenolate mofetil. Int Ophthalmol. 2009;29(3):127–133. Epub 2008 Feb 23.
   PubMedGoogle Scholar
• Taylor SR, Habot-Wilner Z, Pacheco P, et al. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology. 2009;116(4):797–801.
   PubMed Web of Science ®Google Scholar
• Mackensen F, Max R, Becker MD. Interferons and their potential in the treatment of ocular inflammation. Clin Ophthalmol. 2009;3:559–566. Epub 2009 Oct 19.
   PubMedGoogle Scholar
• Deuter CM, et al. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina. 2006;26(7):786–791.
   Google Scholar
• Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91:335–339.
   PubMed Web of Science ®Google Scholar
• Plskova J, Greiner K, Forrester JV. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol. 2007;144:55–61.
   PubMed Web of Science ®Google Scholar
• Deuter CM, Kötter I, Günaydin I, et al. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93(7):906–913. Epub 2009 Mar 24.
   PubMed Web of Science ®Google Scholar
• Sharma SM, Nestel AR, Lee RW, et al. Clinical review: anti-TNFalpha therapies in uveitis—perspective on 5 years of clinical experience. Ocul Immunol Inflamm. 2009;17(6):403–414.
   PubMed Web of Science ®Google Scholar
• Hale S, Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine. 2006; 33:231–237.
   PubMed Web of Science ®Google Scholar
• Dick AD, Forrester JV, Liversidge J, et al. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res. 2004;23(6):617–637.
   PubMed Web of Science ®Google Scholar
• Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007:18:481–486.
   PubMed Web of Science ®Google Scholar
• Markomichelakis NN, Theodossiadis PG, Pantelia E, et al. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138:648–650.
   PubMed Web of Science ®Google Scholar
• Diaz-Llopis M, García-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther. 2008;24(3):351–361.
   PubMed Web of Science ®Google Scholar
• Becker M, Davis J. Vitrectomy in the treatment of uveitis. Am J Ophthalmol. 2005;140(6):1096–1105.
   Google Scholar
• Tranos P, Scott R, Zambarajki H, et al. The effect of pars plana vitrectomy on cystoid macular oedema associated with chronic uveitis: a randomised, controlled pilot study. Br J Ophthalmol. 2006; 90:1107–1110.
   PubMed Web of Science ®Google Scholar
• Markomichelakis NN, Halkiadakis I, Pantelia E, et al. Course of macular edema in uveitis under medical treatment. Ocul Immunol Inflamm. 2007;15:71–79.
   PubMed Web of Science ®Google Scholar
• Gutfleisch M, Spital G, Mingels A, et al. Pars plana vitrectomy with intravitreal triamcinolone: effect on uveitic cystoid macular oedema and treatment limitations. Br J Ophthalmol. 2007;91(3):345–348. Epub 2006 Sep 27.
   PubMed Web of Science ®Google Scholar
• Schaal S, Tezel TH, Kaplan HJ. Surgical intervention in refractory CME—role of posterior hyaloid separation and internal limiting membrane peeling. Ocul Immunol Inflamm. 2008;16:209–210.
   PubMed Web of Science ®Google Scholar
• Garweg JG, Becker M, Lommatzsch A, et al. Update on vitrectomy for pediatric uveitis. Klin Monbl Augenheilkd. 2007;224(6):538–542.
   Google Scholar